Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
説明 | Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. |
ターゲット&IC50 | VEGFR1:33 nM, VEGFR3:0.5 nM, VEGFR2:35 nM |
別名 | HMPL-013 |
分子量 | 393.39 |
分子式 | C21H19N3O5 |
CAS No. | 1194506-26-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6 mg/mL (15.25 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fruquintinib 1194506-26-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR HMPL-013 Inhibitor Vascular endothelial growth factor receptor HMPL013 inhibit HMPL 013 inhibitor